Opinion|Videos|December 23, 2024
MonumenTAL: Key Efficacy Outcomes
Dr Nadeem to summarize the clinical evidence supporting talquetamab use in relapsed/refractory multiple myeloma, including key efficacy outcomes from the monumenTAL trials.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What characteristics make this patient particularly suitable for treatment with a bispecific antibody?
- Can you summarize the clinical evidence supporting talquetamab use in relapsed/refractory multiple myeloma (R/R MM)?
- Could you highlight the primary efficacy outcomes from the monumenTAL trials?
Advertisement
Related to this article
Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care.
Erik Bengtsen, MD, described what sets psycho-oncology apart and how clinicians can open conversations on body image and sexual health.
Erik Bengtsen, MD, explained how antidepressants may improve quality of life and how he typically works with patients who decline favorable treatment.
Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose antidepressant.
Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.
Advertisement
Advertisement
Trending on CancerNetwork
1
Top Poster Takeaways for Prostate Cancer From 2026 ESMO Congress
2
Adjuvant Ribociclib Improves OS at 6 Years in HR+/HER2- Early Breast Cancer
3
Pembrolizumab Plus Chemo Shows Encouraging Activity in NEPC
4
ctDNA Is Prognostic Regardless of Therapy in Cisplatin-Eligible MIBC
5